Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Hepatocellular Carcinoma Non-resectable

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan, Taiwan
Contact: Study coordinator (Rodney Cheng-En Hsieh, MD, PhD) · rodney445@gmail.com · +88633281200

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Munich, Germany · Munich, Germany

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Calgary, Canada · Vancouver, Canada

Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis

Hepatocellular Carcinoma Non-resectable

Abroad (travel likely)RecruitingPHASE2

Grenoble, France · Lille, France

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Pittsburgh, United States · Houston, United States